Back to top

Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher

Read MoreHide Full Article

Amneal Pharmaceuticals, Inc. (AMRX - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $12.35 –$14.01 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after the company reported solid fourth-quarter 2018 results.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Amneal Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.  

Investors interested in the Medical - Drugs industry may consider AIT Therapeutics, Inc. (AITB - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is AMRX going up? Or down? Predict to see what others think:Up or Down

This Could Be the Fastest Way to Grow Wealth in 2019
 
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
 
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
 
Click here to see these breakthrough stocks now >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


AIT Therapeutics, Inc. (AITB) - free report >>

AMNEAL PHARMACEUTICALS, INC. (AMRX) - free report >>

More from Zacks Tale of the Tape

You May Like